Assessment	O
of	O
Interleukin	B:C1705947
-	I:C1705947
17A	I:C1705947
,	O
Interleukin-10	O
and	O
Transforming	O
Growth	I:C1704256
Factor	I:C1704256
-	I:C1704256
Beta1	I:C1704256
Serum	O
Titers	O
in	O
Relapsing	O
Remitting	O
Multiple	O
Sclerosis	I:C0026769
Patients	O
Treated	O
with	O
Avonex	O
,	O
Possible	O
Biomarkers	O
for	O
Treatment	O
Response	I:C0521982
.	O

Assessment	O
of	O
Interleukin	O
-	I:C1705947
17A	I:C1705947
,	O
Interleukin-10	B:C0085295
and	O
Transforming	O
Growth	I:C1704256
Factor	I:C1704256
-	I:C1704256
Beta1	I:C1704256
Serum	O
Titers	O
in	O
Relapsing	O
Remitting	O
Multiple	O
Sclerosis	I:C0026769
Patients	O
Treated	O
with	O
Avonex	O
,	O
Possible	O
Biomarkers	O
for	O
Treatment	O
Response	I:C0521982
.	O

Assessment	O
of	O
Interleukin	O
-	I:C1705947
17A	I:C1705947
,	O
Interleukin-10	O
and	O
Transforming	B:C1704256
Growth	I:C1704256
Factor	I:C1704256
-	I:C1704256
Beta1	I:C1704256
Serum	O
Titers	O
in	O
Relapsing	O
Remitting	O
Multiple	O
Sclerosis	I:C0026769
Patients	O
Treated	O
with	O
Avonex	O
,	O
Possible	O
Biomarkers	O
for	O
Treatment	O
Response	I:C0521982
.	O

Assessment	O
of	O
Interleukin	O
-	I:C1705947
17A	I:C1705947
,	O
Interleukin-10	O
and	O
Transforming	O
Growth	I:C1704256
Factor	I:C1704256
-	I:C1704256
Beta1	I:C1704256
Serum	B:C0229671
Titers	O
in	O
Relapsing	O
Remitting	O
Multiple	O
Sclerosis	I:C0026769
Patients	O
Treated	O
with	O
Avonex	O
,	O
Possible	O
Biomarkers	O
for	O
Treatment	O
Response	I:C0521982
.	O

Assessment	O
of	O
Interleukin	O
-	I:C1705947
17A	I:C1705947
,	O
Interleukin-10	O
and	O
Transforming	O
Growth	I:C1704256
Factor	I:C1704256
-	I:C1704256
Beta1	I:C1704256
Serum	O
Titers	O
in	O
Relapsing	O
Remitting	O
Multiple	B:C0026769
Sclerosis	I:C0026769
Patients	O
Treated	O
with	O
Avonex	O
,	O
Possible	O
Biomarkers	O
for	O
Treatment	O
Response	I:C0521982
.	O

Assessment	O
of	O
Interleukin	O
-	I:C1705947
17A	I:C1705947
,	O
Interleukin-10	O
and	O
Transforming	O
Growth	I:C1704256
Factor	I:C1704256
-	I:C1704256
Beta1	I:C1704256
Serum	O
Titers	O
in	O
Relapsing	O
Remitting	O
Multiple	O
Sclerosis	I:C0026769
Patients	O
Treated	O
with	O
Avonex	B:C0594372
,	O
Possible	O
Biomarkers	O
for	O
Treatment	O
Response	I:C0521982
.	O

Assessment	O
of	O
Interleukin	O
-	I:C1705947
17A	I:C1705947
,	O
Interleukin-10	O
and	O
Transforming	O
Growth	I:C1704256
Factor	I:C1704256
-	I:C1704256
Beta1	I:C1704256
Serum	O
Titers	O
in	O
Relapsing	O
Remitting	O
Multiple	O
Sclerosis	I:C0026769
Patients	O
Treated	O
with	O
Avonex	O
,	O
Possible	B:C0332149
Biomarkers	O
for	O
Treatment	O
Response	I:C0521982
.	O

Assessment	O
of	O
Interleukin	O
-	I:C1705947
17A	I:C1705947
,	O
Interleukin-10	O
and	O
Transforming	O
Growth	I:C1704256
Factor	I:C1704256
-	I:C1704256
Beta1	I:C1704256
Serum	O
Titers	O
in	O
Relapsing	O
Remitting	O
Multiple	O
Sclerosis	I:C0026769
Patients	O
Treated	O
with	O
Avonex	O
,	O
Possible	O
Biomarkers	B:C0005516
for	O
Treatment	O
Response	I:C0521982
.	O

Assessment	O
of	O
Interleukin	O
-	I:C1705947
17A	I:C1705947
,	O
Interleukin-10	O
and	O
Transforming	O
Growth	I:C1704256
Factor	I:C1704256
-	I:C1704256
Beta1	I:C1704256
Serum	O
Titers	O
in	O
Relapsing	O
Remitting	O
Multiple	O
Sclerosis	I:C0026769
Patients	O
Treated	O
with	O
Avonex	O
,	O
Possible	O
Biomarkers	O
for	O
Treatment	B:C0521982
Response	I:C0521982
.	O

Individual	B:C0237401
response	O
to	O
interferon	O
beta	I:C0254119
(	I:C0254119
IFN	I:C0254119
-β)	I:C0254119
1a	I:C0254119
treatment	O
is	O
heterogeneous	O
in	O
multiple	O
sclerosis	I:C0026769
(	O
multiple	O
sclerosis	I:C0026769
)	O
.	O

Individual	O
response	B:C0521982
to	O
interferon	O
beta	I:C0254119
(	I:C0254119
IFN	I:C0254119
-β)	I:C0254119
1a	I:C0254119
treatment	O
is	O
heterogeneous	O
in	O
multiple	O
sclerosis	I:C0026769
(	O
multiple	O
sclerosis	I:C0026769
)	O
.	O

Individual	O
response	O
to	O
interferon	B:C0254119
beta	I:C0254119
(	I:C0254119
IFN	I:C0254119
-β)	I:C0254119
1a	I:C0254119
treatment	O
is	O
heterogeneous	O
in	O
multiple	O
sclerosis	I:C0026769
(	O
multiple	O
sclerosis	I:C0026769
)	O
.	O

Individual	O
response	O
to	O
interferon	O
beta	I:C0254119
(	I:C0254119
IFN	I:C0254119
-β)	I:C0254119
1a	I:C0254119
treatment	O
is	O
heterogeneous	O
in	O
multiple	B:C0026769
sclerosis	I:C0026769
(	O
multiple	O
sclerosis	I:C0026769
)	O
.	O

Individual	O
response	O
to	O
interferon	O
beta	I:C0254119
(	I:C0254119
IFN	I:C0254119
-β)	I:C0254119
1a	I:C0254119
treatment	O
is	O
heterogeneous	O
in	O
multiple	O
sclerosis	I:C0026769
(	O
multiple	B:C0026769
sclerosis	I:C0026769
)	O
.	O

Our	O
objective	B:C0018017
was	O
to	O
find	O
a	O
connection	O
between	O
serum	O
levels	O
of	O
interleukin	O
(	I:C0085295
IL	I:C0085295
)	I:C0085295
-	I:C0085295
10	I:C0085295
,	O
IL	O
-	I:C0384648
17	I:C0384648
and	O
transforming	O
growth	I:C1704256
factor	I:C1704256
beta	I:C1704256
(	I:C1704256
TGF	I:C1704256
-	I:C1704256
β)	I:C1704256
1	I:C1704256
in	O
multiple	O
sclerosis	I:C0026769
patients	O
treated	O
with	O
interferon	O
beta	I:C0015980
in	O
order	O
to	O
identify	O
the	O
nonresponders	O
(	O
nonresponders	O
)	O
.	O

Our	O
objective	O
was	O
to	O
find	O
a	O
connection	B:C0449379
between	O
serum	O
levels	O
of	O
interleukin	O
(	I:C0085295
IL	I:C0085295
)	I:C0085295
-	I:C0085295
10	I:C0085295
,	O
IL	O
-	I:C0384648
17	I:C0384648
and	O
transforming	O
growth	I:C1704256
factor	I:C1704256
beta	I:C1704256
(	I:C1704256
TGF	I:C1704256
-	I:C1704256
β)	I:C1704256
1	I:C1704256
in	O
multiple	O
sclerosis	I:C0026769
patients	O
treated	O
with	O
interferon	O
beta	I:C0015980
in	O
order	O
to	O
identify	O
the	O
nonresponders	O
(	O
nonresponders	O
)	O
.	O

Our	O
objective	O
was	O
to	O
find	O
a	O
connection	O
between	O
serum	B:C0229671
levels	O
of	O
interleukin	O
(	I:C0085295
IL	I:C0085295
)	I:C0085295
-	I:C0085295
10	I:C0085295
,	O
IL	O
-	I:C0384648
17	I:C0384648
and	O
transforming	O
growth	I:C1704256
factor	I:C1704256
beta	I:C1704256
(	I:C1704256
TGF	I:C1704256
-	I:C1704256
β)	I:C1704256
1	I:C1704256
in	O
multiple	O
sclerosis	I:C0026769
patients	O
treated	O
with	O
interferon	O
beta	I:C0015980
in	O
order	O
to	O
identify	O
the	O
nonresponders	O
(	O
nonresponders	O
)	O
.	O

Our	O
objective	O
was	O
to	O
find	O
a	O
connection	O
between	O
serum	O
levels	O
of	O
interleukin	B:C0085295
(	I:C0085295
IL	I:C0085295
)	I:C0085295
-	I:C0085295
10	I:C0085295
,	O
IL	O
-	I:C0384648
17	I:C0384648
and	O
transforming	O
growth	I:C1704256
factor	I:C1704256
beta	I:C1704256
(	I:C1704256
TGF	I:C1704256
-	I:C1704256
β)	I:C1704256
1	I:C1704256
in	O
multiple	O
sclerosis	I:C0026769
patients	O
treated	O
with	O
interferon	O
beta	I:C0015980
in	O
order	O
to	O
identify	O
the	O
nonresponders	O
(	O
nonresponders	O
)	O
.	O

Our	O
objective	O
was	O
to	O
find	O
a	O
connection	O
between	O
serum	O
levels	O
of	O
interleukin	O
(	I:C0085295
IL	I:C0085295
)	I:C0085295
-	I:C0085295
10	I:C0085295
,	O
IL	B:C0384648
-	I:C0384648
17	I:C0384648
and	O
transforming	O
growth	I:C1704256
factor	I:C1704256
beta	I:C1704256
(	I:C1704256
TGF	I:C1704256
-	I:C1704256
β)	I:C1704256
1	I:C1704256
in	O
multiple	O
sclerosis	I:C0026769
patients	O
treated	O
with	O
interferon	O
beta	I:C0015980
in	O
order	O
to	O
identify	O
the	O
nonresponders	O
(	O
nonresponders	O
)	O
.	O

Our	O
objective	O
was	O
to	O
find	O
a	O
connection	O
between	O
serum	O
levels	O
of	O
interleukin	O
(	I:C0085295
IL	I:C0085295
)	I:C0085295
-	I:C0085295
10	I:C0085295
,	O
IL	O
-	I:C0384648
17	I:C0384648
and	O
transforming	B:C1704256
growth	I:C1704256
factor	I:C1704256
beta	I:C1704256
(	I:C1704256
TGF	I:C1704256
-	I:C1704256
β)	I:C1704256
1	I:C1704256
in	O
multiple	O
sclerosis	I:C0026769
patients	O
treated	O
with	O
interferon	O
beta	I:C0015980
in	O
order	O
to	O
identify	O
the	O
nonresponders	O
(	O
nonresponders	O
)	O
.	O

Our	O
objective	O
was	O
to	O
find	O
a	O
connection	O
between	O
serum	O
levels	O
of	O
interleukin	O
(	I:C0085295
IL	I:C0085295
)	I:C0085295
-	I:C0085295
10	I:C0085295
,	O
IL	O
-	I:C0384648
17	I:C0384648
and	O
transforming	O
growth	I:C1704256
factor	I:C1704256
beta	I:C1704256
(	I:C1704256
TGF	I:C1704256
-	I:C1704256
β)	I:C1704256
1	I:C1704256
in	O
multiple	B:C0026769
sclerosis	I:C0026769
patients	O
treated	O
with	O
interferon	O
beta	I:C0015980
in	O
order	O
to	O
identify	O
the	O
nonresponders	O
(	O
nonresponders	O
)	O
.	O

Our	O
objective	O
was	O
to	O
find	O
a	O
connection	O
between	O
serum	O
levels	O
of	O
interleukin	O
(	I:C0085295
IL	I:C0085295
)	I:C0085295
-	I:C0085295
10	I:C0085295
,	O
IL	O
-	I:C0384648
17	I:C0384648
and	O
transforming	O
growth	I:C1704256
factor	I:C1704256
beta	I:C1704256
(	I:C1704256
TGF	I:C1704256
-	I:C1704256
β)	I:C1704256
1	I:C1704256
in	O
multiple	O
sclerosis	I:C0026769
patients	O
treated	O
with	O
interferon	B:C0015980
beta	I:C0015980
in	O
order	O
to	O
identify	O
the	O
nonresponders	O
(	O
nonresponders	O
)	O
.	O

Our	O
objective	O
was	O
to	O
find	O
a	O
connection	O
between	O
serum	O
levels	O
of	O
interleukin	O
(	I:C0085295
IL	I:C0085295
)	I:C0085295
-	I:C0085295
10	I:C0085295
,	O
IL	O
-	I:C0384648
17	I:C0384648
and	O
transforming	O
growth	I:C1704256
factor	I:C1704256
beta	I:C1704256
(	I:C1704256
TGF	I:C1704256
-	I:C1704256
β)	I:C1704256
1	I:C1704256
in	O
multiple	O
sclerosis	I:C0026769
patients	O
treated	O
with	O
interferon	O
beta	I:C0015980
in	O
order	O
to	O
identify	B:C0243095
the	O
nonresponders	O
(	O
nonresponders	O
)	O
.	O

Our	O
objective	O
was	O
to	O
find	O
a	O
connection	O
between	O
serum	O
levels	O
of	O
interleukin	O
(	I:C0085295
IL	I:C0085295
)	I:C0085295
-	I:C0085295
10	I:C0085295
,	O
IL	O
-	I:C0384648
17	I:C0384648
and	O
transforming	O
growth	I:C1704256
factor	I:C1704256
beta	I:C1704256
(	I:C1704256
TGF	I:C1704256
-	I:C1704256
β)	I:C1704256
1	I:C1704256
in	O
multiple	O
sclerosis	I:C0026769
patients	O
treated	O
with	O
interferon	O
beta	I:C0015980
in	O
order	O
to	O
identify	O
the	O
nonresponders	B:C0243095
(	O
nonresponders	O
)	O
.	O

Our	O
objective	O
was	O
to	O
find	O
a	O
connection	O
between	O
serum	O
levels	O
of	O
interleukin	O
(	I:C0085295
IL	I:C0085295
)	I:C0085295
-	I:C0085295
10	I:C0085295
,	O
IL	O
-	I:C0384648
17	I:C0384648
and	O
transforming	O
growth	I:C1704256
factor	I:C1704256
beta	I:C1704256
(	I:C1704256
TGF	I:C1704256
-	I:C1704256
β)	I:C1704256
1	I:C1704256
in	O
multiple	O
sclerosis	I:C0026769
patients	O
treated	O
with	O
interferon	O
beta	I:C0015980
in	O
order	O
to	O
identify	O
the	O
nonresponders	O
(	O
nonresponders	B:C0243095
)	O
.	O

We	O
included	O
in	O
the	O
study	B:C0008972
32	O
healthy	O
subjects	I:C1708335
and	O
32	O
multiple	O
sclerosis	I:C0026769
patients	O
:	O
10	O
naive	O
,	O
10	O
early	O
treated	O
and	O
12	O
late	O
treated	O
with	O
INF	O
-	I:C0254119
β	I:C0254119
1a	I:C0254119
.	O

We	O
included	O
in	O
the	O
study	O
32	O
healthy	B:C1708335
subjects	I:C1708335
and	O
32	O
multiple	O
sclerosis	I:C0026769
patients	O
:	O
10	O
naive	O
,	O
10	O
early	O
treated	O
and	O
12	O
late	O
treated	O
with	O
INF	O
-	I:C0254119
β	I:C0254119
1a	I:C0254119
.	O

We	O
included	O
in	O
the	O
study	O
32	O
healthy	O
subjects	I:C1708335
and	O
32	O
multiple	B:C0026769
sclerosis	I:C0026769
patients	O
:	O
10	O
naive	O
,	O
10	O
early	O
treated	O
and	O
12	O
late	O
treated	O
with	O
INF	O
-	I:C0254119
β	I:C0254119
1a	I:C0254119
.	O

We	O
included	O
in	O
the	O
study	O
32	O
healthy	O
subjects	I:C1708335
and	O
32	O
multiple	O
sclerosis	I:C0026769
patients	O
:	O
10	O
naive	O
,	O
10	O
early	O
treated	O
and	O
12	O
late	O
treated	O
with	O
INF	B:C0254119
-	I:C0254119
β	I:C0254119
1a	I:C0254119
.	O

Serum	B:C0229671
determination	O
of	O
cytokines	O
and	O
brain	O
MRI	I:C0412675
were	O
performed	O
at	O
the	O
beginning	O
of	O
the	O
study	O
,	O
after	O
6	O
and	O
12	O
months	O
.	O

Serum	O
determination	B:C1148554
of	O
cytokines	O
and	O
brain	O
MRI	I:C0412675
were	O
performed	O
at	O
the	O
beginning	O
of	O
the	O
study	O
,	O
after	O
6	O
and	O
12	O
months	O
.	O

Serum	O
determination	O
of	O
cytokines	B:C0079189
and	O
brain	O
MRI	I:C0412675
were	O
performed	O
at	O
the	O
beginning	O
of	O
the	O
study	O
,	O
after	O
6	O
and	O
12	O
months	O
.	O

Serum	O
determination	O
of	O
cytokines	O
and	O
brain	B:C0412675
MRI	I:C0412675
were	O
performed	O
at	O
the	O
beginning	O
of	O
the	O
study	O
,	O
after	O
6	O
and	O
12	O
months	O
.	O

Serum	O
determination	O
of	O
cytokines	O
and	O
brain	O
MRI	I:C0412675
were	O
performed	O
at	O
the	O
beginning	O
of	O
the	O
study	B:C0008972
,	O
after	O
6	O
and	O
12	O
months	O
.	O

Rio	O
score	O
was	O
calculated	O
at	O
the	O
end	O
of	O
the	O
study	B:C0008972
.	O

multiple	B:C0026769
sclerosis	I:C0026769
patients	O
had	O
initially	O
a	O
significant	O
higher	O
level	O
of	O
IL	O
-	I:C0384648
17	I:C0384648
and	O
a	O
lower	O
level	O
of	O
TGF	O
-	I:C1704256
β	I:C1704256
1	I:C1704256
compared	O
to	O
healthy	O
subjects	I:C1708335
.	O

multiple	O
sclerosis	I:C0026769
patients	O
had	O
initially	O
a	O
significant	O
higher	O
level	O
of	O
IL	B:C0384648
-	I:C0384648
17	I:C0384648
and	O
a	O
lower	O
level	O
of	O
TGF	O
-	I:C1704256
β	I:C1704256
1	I:C1704256
compared	O
to	O
healthy	O
subjects	I:C1708335
.	O

multiple	O
sclerosis	I:C0026769
patients	O
had	O
initially	O
a	O
significant	O
higher	O
level	O
of	O
IL	O
-	I:C0384648
17	I:C0384648
and	O
a	O
lower	O
level	O
of	O
TGF	B:C1704256
-	I:C1704256
β	I:C1704256
1	I:C1704256
compared	O
to	O
healthy	O
subjects	I:C1708335
.	O

multiple	O
sclerosis	I:C0026769
patients	O
had	O
initially	O
a	O
significant	O
higher	O
level	O
of	O
IL	O
-	I:C0384648
17	I:C0384648
and	O
a	O
lower	O
level	O
of	O
TGF	O
-	I:C1704256
β	I:C1704256
1	I:C1704256
compared	O
to	O
healthy	B:C1708335
subjects	I:C1708335
.	O

IL	B:C0384648
-	I:C0384648
17	I:C0384648
level	O
in	O
early	O
treated	O
patients	O
was	O
significantly	O
lower	O
compared	O
to	O
the	O
naive	O
and	O
late	O
treated	O
groups	O
.	O

IL	O
-	I:C0384648
17	I:C0384648
level	O
in	O
early	O
treated	O
patients	O
was	O
significantly	O
lower	O
compared	O
to	O
the	O
naive	O
and	O
late	O
treated	O
groups	B:C0687744
.	O

INF	B:C0254119
-	I:C0254119
β	I:C0254119
1a	I:C0254119
treatment	O
significantly	O
increased	O
IL	O
-	I:C0085295
10	I:C0085295
and	O
decreased	O
IL	O
-	I:C0384648
17	I:C0384648
levels	O
.	O

INF	O
-	I:C0254119
β	I:C0254119
1a	I:C0254119
treatment	O
significantly	O
increased	O
IL	B:C0085295
-	I:C0085295
10	I:C0085295
and	O
decreased	O
IL	O
-	I:C0384648
17	I:C0384648
levels	O
.	O

INF	O
-	I:C0254119
β	I:C0254119
1a	I:C0254119
treatment	O
significantly	O
increased	O
IL	O
-	I:C0085295
10	I:C0085295
and	O
decreased	O
IL	B:C0384648
-	I:C0384648
17	I:C0384648
levels	O
.	O

Initial	O
low	O
levels	O
of	O
IL	B:C0085295
-	I:C0085295
10	I:C0085295
were	O
associated	O
with	O
an	O
increase	O
in	O
physical	O
disability	I:C0520817
.	O

Initial	O
low	O
levels	O
of	O
IL	O
-	I:C0085295
10	I:C0085295
were	O
associated	O
with	O
an	O
increase	O
in	O
physical	B:C0520817
disability	I:C0520817
.	O

IL	B:C0384648
-	I:C0384648
17	I:C0384648
levels	O
positively	O
correlated	O
with	O
the	O
number	O
of	O
relapses	O
and	O
MRI	O
activity	O
.	O

IL	O
-	I:C0384648
17	I:C0384648
levels	O
positively	O
correlated	O
with	O
the	O
number	O
of	O
relapses	O
and	O
MRI	B:C0024485
activity	O
.	O

Nine	O
patients	O
were	O
nonresponders	B:C0243095
to	O
Avonex	O
.	O

Nine	O
patients	O
were	O
nonresponders	O
to	O
Avonex	B:C0594372
.	O

Patients	O
with	O
a	O
Rio	O
score	O
of	O
3	O
had	O
higher	O
initial	O
levels	O
of	O
IL	B:C0384648
-	I:C0384648
17	I:C0384648
and	O
those	O
with	O
a	O
Rio	O
score	O
of	O
0	O
had	O
higher	O
initial	O
levels	O
of	O
IL	O
-	I:C0085295
10	I:C0085295
and	O
TGF	O
-	I:C1704256
β	I:C1704256
1	I:C1704256
.	O
IFN	O
-	I:C0254119
β	I:C0254119
1a	I:C0254119
decreased	O
IL	O
-	I:C0384648
17	I:C0384648
and	O
increased	O
IL	O
-	I:C0085295
10	I:C0085295
seric	O
levels	O
;	O
IL	O
-	I:C0384648
17	I:C0384648
significantly	O
correlated	O
with	O
multiple	O
sclerosis	I:C0026769
activity	O
;	O
TGF	O
-	I:C1704256
β	I:C1704256
1	I:C1704256
activity	O
is	O
titer	O
-	O
dependent	O
,	O
increased	O
levels	O
were	O
associated	O
with	O
IL	O
-	I:C0384648
17	I:C0384648
inhibition	O
;	O
nonresponders	O
patients	O
to	O
IFN	O
-	I:C0254119
β	I:C0254119
1a	I:C0254119
will	O
have	O
initial	O
high	O
IL	O
-	I:C0384648
17	I:C0384648
and	O
low	O
IL	O
-	I:C0085295
10	I:C0085295
and	O
TGF	O
-β	I:C0040690
seric	O
levels	O
.	O

Patients	O
with	O
a	O
Rio	O
score	O
of	O
3	O
had	O
higher	O
initial	O
levels	O
of	O
IL	O
-	I:C0384648
17	I:C0384648
and	O
those	O
with	O
a	O
Rio	O
score	O
of	O
0	O
had	O
higher	O
initial	O
levels	O
of	O
IL	B:C0085295
-	I:C0085295
10	I:C0085295
and	O
TGF	O
-	I:C1704256
β	I:C1704256
1	I:C1704256
.	O
IFN	O
-	I:C0254119
β	I:C0254119
1a	I:C0254119
decreased	O
IL	O
-	I:C0384648
17	I:C0384648
and	O
increased	O
IL	O
-	I:C0085295
10	I:C0085295
seric	O
levels	O
;	O
IL	O
-	I:C0384648
17	I:C0384648
significantly	O
correlated	O
with	O
multiple	O
sclerosis	I:C0026769
activity	O
;	O
TGF	O
-	I:C1704256
β	I:C1704256
1	I:C1704256
activity	O
is	O
titer	O
-	O
dependent	O
,	O
increased	O
levels	O
were	O
associated	O
with	O
IL	O
-	I:C0384648
17	I:C0384648
inhibition	O
;	O
nonresponders	O
patients	O
to	O
IFN	O
-	I:C0254119
β	I:C0254119
1a	I:C0254119
will	O
have	O
initial	O
high	O
IL	O
-	I:C0384648
17	I:C0384648
and	O
low	O
IL	O
-	I:C0085295
10	I:C0085295
and	O
TGF	O
-β	I:C0040690
seric	O
levels	O
.	O

Patients	O
with	O
a	O
Rio	O
score	O
of	O
3	O
had	O
higher	O
initial	O
levels	O
of	O
IL	O
-	I:C0384648
17	I:C0384648
and	O
those	O
with	O
a	O
Rio	O
score	O
of	O
0	O
had	O
higher	O
initial	O
levels	O
of	O
IL	O
-	I:C0085295
10	I:C0085295
and	O
TGF	B:C1704256
-	I:C1704256
β	I:C1704256
1	I:C1704256
.	O
IFN	O
-	I:C0254119
β	I:C0254119
1a	I:C0254119
decreased	O
IL	O
-	I:C0384648
17	I:C0384648
and	O
increased	O
IL	O
-	I:C0085295
10	I:C0085295
seric	O
levels	O
;	O
IL	O
-	I:C0384648
17	I:C0384648
significantly	O
correlated	O
with	O
multiple	O
sclerosis	I:C0026769
activity	O
;	O
TGF	O
-	I:C1704256
β	I:C1704256
1	I:C1704256
activity	O
is	O
titer	O
-	O
dependent	O
,	O
increased	O
levels	O
were	O
associated	O
with	O
IL	O
-	I:C0384648
17	I:C0384648
inhibition	O
;	O
nonresponders	O
patients	O
to	O
IFN	O
-	I:C0254119
β	I:C0254119
1a	I:C0254119
will	O
have	O
initial	O
high	O
IL	O
-	I:C0384648
17	I:C0384648
and	O
low	O
IL	O
-	I:C0085295
10	I:C0085295
and	O
TGF	O
-β	I:C0040690
seric	O
levels	O
.	O

Patients	O
with	O
a	O
Rio	O
score	O
of	O
3	O
had	O
higher	O
initial	O
levels	O
of	O
IL	O
-	I:C0384648
17	I:C0384648
and	O
those	O
with	O
a	O
Rio	O
score	O
of	O
0	O
had	O
higher	O
initial	O
levels	O
of	O
IL	O
-	I:C0085295
10	I:C0085295
and	O
TGF	O
-	I:C1704256
β	I:C1704256
1	I:C1704256
.	O
IFN	B:C0254119
-	I:C0254119
β	I:C0254119
1a	I:C0254119
decreased	O
IL	O
-	I:C0384648
17	I:C0384648
and	O
increased	O
IL	O
-	I:C0085295
10	I:C0085295
seric	O
levels	O
;	O
IL	O
-	I:C0384648
17	I:C0384648
significantly	O
correlated	O
with	O
multiple	O
sclerosis	I:C0026769
activity	O
;	O
TGF	O
-	I:C1704256
β	I:C1704256
1	I:C1704256
activity	O
is	O
titer	O
-	O
dependent	O
,	O
increased	O
levels	O
were	O
associated	O
with	O
IL	O
-	I:C0384648
17	I:C0384648
inhibition	O
;	O
nonresponders	O
patients	O
to	O
IFN	O
-	I:C0254119
β	I:C0254119
1a	I:C0254119
will	O
have	O
initial	O
high	O
IL	O
-	I:C0384648
17	I:C0384648
and	O
low	O
IL	O
-	I:C0085295
10	I:C0085295
and	O
TGF	O
-β	I:C0040690
seric	O
levels	O
.	O

Patients	O
with	O
a	O
Rio	O
score	O
of	O
3	O
had	O
higher	O
initial	O
levels	O
of	O
IL	O
-	I:C0384648
17	I:C0384648
and	O
those	O
with	O
a	O
Rio	O
score	O
of	O
0	O
had	O
higher	O
initial	O
levels	O
of	O
IL	O
-	I:C0085295
10	I:C0085295
and	O
TGF	O
-	I:C1704256
β	I:C1704256
1	I:C1704256
.	O
IFN	O
-	I:C0254119
β	I:C0254119
1a	I:C0254119
decreased	O
IL	B:C0384648
-	I:C0384648
17	I:C0384648
and	O
increased	O
IL	O
-	I:C0085295
10	I:C0085295
seric	O
levels	O
;	O
IL	O
-	I:C0384648
17	I:C0384648
significantly	O
correlated	O
with	O
multiple	O
sclerosis	I:C0026769
activity	O
;	O
TGF	O
-	I:C1704256
β	I:C1704256
1	I:C1704256
activity	O
is	O
titer	O
-	O
dependent	O
,	O
increased	O
levels	O
were	O
associated	O
with	O
IL	O
-	I:C0384648
17	I:C0384648
inhibition	O
;	O
nonresponders	O
patients	O
to	O
IFN	O
-	I:C0254119
β	I:C0254119
1a	I:C0254119
will	O
have	O
initial	O
high	O
IL	O
-	I:C0384648
17	I:C0384648
and	O
low	O
IL	O
-	I:C0085295
10	I:C0085295
and	O
TGF	O
-β	I:C0040690
seric	O
levels	O
.	O

Patients	O
with	O
a	O
Rio	O
score	O
of	O
3	O
had	O
higher	O
initial	O
levels	O
of	O
IL	O
-	I:C0384648
17	I:C0384648
and	O
those	O
with	O
a	O
Rio	O
score	O
of	O
0	O
had	O
higher	O
initial	O
levels	O
of	O
IL	O
-	I:C0085295
10	I:C0085295
and	O
TGF	O
-	I:C1704256
β	I:C1704256
1	I:C1704256
.	O
IFN	O
-	I:C0254119
β	I:C0254119
1a	I:C0254119
decreased	O
IL	O
-	I:C0384648
17	I:C0384648
and	O
increased	O
IL	B:C0085295
-	I:C0085295
10	I:C0085295
seric	O
levels	O
;	O
IL	O
-	I:C0384648
17	I:C0384648
significantly	O
correlated	O
with	O
multiple	O
sclerosis	I:C0026769
activity	O
;	O
TGF	O
-	I:C1704256
β	I:C1704256
1	I:C1704256
activity	O
is	O
titer	O
-	O
dependent	O
,	O
increased	O
levels	O
were	O
associated	O
with	O
IL	O
-	I:C0384648
17	I:C0384648
inhibition	O
;	O
nonresponders	O
patients	O
to	O
IFN	O
-	I:C0254119
β	I:C0254119
1a	I:C0254119
will	O
have	O
initial	O
high	O
IL	O
-	I:C0384648
17	I:C0384648
and	O
low	O
IL	O
-	I:C0085295
10	I:C0085295
and	O
TGF	O
-β	I:C0040690
seric	O
levels	O
.	O

Patients	O
with	O
a	O
Rio	O
score	O
of	O
3	O
had	O
higher	O
initial	O
levels	O
of	O
IL	O
-	I:C0384648
17	I:C0384648
and	O
those	O
with	O
a	O
Rio	O
score	O
of	O
0	O
had	O
higher	O
initial	O
levels	O
of	O
IL	O
-	I:C0085295
10	I:C0085295
and	O
TGF	O
-	I:C1704256
β	I:C1704256
1	I:C1704256
.	O
IFN	O
-	I:C0254119
β	I:C0254119
1a	I:C0254119
decreased	O
IL	O
-	I:C0384648
17	I:C0384648
and	O
increased	O
IL	O
-	I:C0085295
10	I:C0085295
seric	B:C0229671
levels	O
;	O
IL	O
-	I:C0384648
17	I:C0384648
significantly	O
correlated	O
with	O
multiple	O
sclerosis	I:C0026769
activity	O
;	O
TGF	O
-	I:C1704256
β	I:C1704256
1	I:C1704256
activity	O
is	O
titer	O
-	O
dependent	O
,	O
increased	O
levels	O
were	O
associated	O
with	O
IL	O
-	I:C0384648
17	I:C0384648
inhibition	O
;	O
nonresponders	O
patients	O
to	O
IFN	O
-	I:C0254119
β	I:C0254119
1a	I:C0254119
will	O
have	O
initial	O
high	O
IL	O
-	I:C0384648
17	I:C0384648
and	O
low	O
IL	O
-	I:C0085295
10	I:C0085295
and	O
TGF	O
-β	I:C0040690
seric	O
levels	O
.	O

Patients	O
with	O
a	O
Rio	O
score	O
of	O
3	O
had	O
higher	O
initial	O
levels	O
of	O
IL	O
-	I:C0384648
17	I:C0384648
and	O
those	O
with	O
a	O
Rio	O
score	O
of	O
0	O
had	O
higher	O
initial	O
levels	O
of	O
IL	O
-	I:C0085295
10	I:C0085295
and	O
TGF	O
-	I:C1704256
β	I:C1704256
1	I:C1704256
.	O
IFN	O
-	I:C0254119
β	I:C0254119
1a	I:C0254119
decreased	O
IL	O
-	I:C0384648
17	I:C0384648
and	O
increased	O
IL	O
-	I:C0085295
10	I:C0085295
seric	O
levels	O
;	O
IL	B:C0384648
-	I:C0384648
17	I:C0384648
significantly	O
correlated	O
with	O
multiple	O
sclerosis	I:C0026769
activity	O
;	O
TGF	O
-	I:C1704256
β	I:C1704256
1	I:C1704256
activity	O
is	O
titer	O
-	O
dependent	O
,	O
increased	O
levels	O
were	O
associated	O
with	O
IL	O
-	I:C0384648
17	I:C0384648
inhibition	O
;	O
nonresponders	O
patients	O
to	O
IFN	O
-	I:C0254119
β	I:C0254119
1a	I:C0254119
will	O
have	O
initial	O
high	O
IL	O
-	I:C0384648
17	I:C0384648
and	O
low	O
IL	O
-	I:C0085295
10	I:C0085295
and	O
TGF	O
-β	I:C0040690
seric	O
levels	O
.	O

Patients	O
with	O
a	O
Rio	O
score	O
of	O
3	O
had	O
higher	O
initial	O
levels	O
of	O
IL	O
-	I:C0384648
17	I:C0384648
and	O
those	O
with	O
a	O
Rio	O
score	O
of	O
0	O
had	O
higher	O
initial	O
levels	O
of	O
IL	O
-	I:C0085295
10	I:C0085295
and	O
TGF	O
-	I:C1704256
β	I:C1704256
1	I:C1704256
.	O
IFN	O
-	I:C0254119
β	I:C0254119
1a	I:C0254119
decreased	O
IL	O
-	I:C0384648
17	I:C0384648
and	O
increased	O
IL	O
-	I:C0085295
10	I:C0085295
seric	O
levels	O
;	O
IL	O
-	I:C0384648
17	I:C0384648
significantly	O
correlated	O
with	O
multiple	B:C0026769
sclerosis	I:C0026769
activity	O
;	O
TGF	O
-	I:C1704256
β	I:C1704256
1	I:C1704256
activity	O
is	O
titer	O
-	O
dependent	O
,	O
increased	O
levels	O
were	O
associated	O
with	O
IL	O
-	I:C0384648
17	I:C0384648
inhibition	O
;	O
nonresponders	O
patients	O
to	O
IFN	O
-	I:C0254119
β	I:C0254119
1a	I:C0254119
will	O
have	O
initial	O
high	O
IL	O
-	I:C0384648
17	I:C0384648
and	O
low	O
IL	O
-	I:C0085295
10	I:C0085295
and	O
TGF	O
-β	I:C0040690
seric	O
levels	O
.	O

Patients	O
with	O
a	O
Rio	O
score	O
of	O
3	O
had	O
higher	O
initial	O
levels	O
of	O
IL	O
-	I:C0384648
17	I:C0384648
and	O
those	O
with	O
a	O
Rio	O
score	O
of	O
0	O
had	O
higher	O
initial	O
levels	O
of	O
IL	O
-	I:C0085295
10	I:C0085295
and	O
TGF	O
-	I:C1704256
β	I:C1704256
1	I:C1704256
.	O
IFN	O
-	I:C0254119
β	I:C0254119
1a	I:C0254119
decreased	O
IL	O
-	I:C0384648
17	I:C0384648
and	O
increased	O
IL	O
-	I:C0085295
10	I:C0085295
seric	O
levels	O
;	O
IL	O
-	I:C0384648
17	I:C0384648
significantly	O
correlated	O
with	O
multiple	O
sclerosis	I:C0026769
activity	O
;	O
TGF	B:C1704256
-	I:C1704256
β	I:C1704256
1	I:C1704256
activity	O
is	O
titer	O
-	O
dependent	O
,	O
increased	O
levels	O
were	O
associated	O
with	O
IL	O
-	I:C0384648
17	I:C0384648
inhibition	O
;	O
nonresponders	O
patients	O
to	O
IFN	O
-	I:C0254119
β	I:C0254119
1a	I:C0254119
will	O
have	O
initial	O
high	O
IL	O
-	I:C0384648
17	I:C0384648
and	O
low	O
IL	O
-	I:C0085295
10	I:C0085295
and	O
TGF	O
-β	I:C0040690
seric	O
levels	O
.	O

Patients	O
with	O
a	O
Rio	O
score	O
of	O
3	O
had	O
higher	O
initial	O
levels	O
of	O
IL	O
-	I:C0384648
17	I:C0384648
and	O
those	O
with	O
a	O
Rio	O
score	O
of	O
0	O
had	O
higher	O
initial	O
levels	O
of	O
IL	O
-	I:C0085295
10	I:C0085295
and	O
TGF	O
-	I:C1704256
β	I:C1704256
1	I:C1704256
.	O
IFN	O
-	I:C0254119
β	I:C0254119
1a	I:C0254119
decreased	O
IL	O
-	I:C0384648
17	I:C0384648
and	O
increased	O
IL	O
-	I:C0085295
10	I:C0085295
seric	O
levels	O
;	O
IL	O
-	I:C0384648
17	I:C0384648
significantly	O
correlated	O
with	O
multiple	O
sclerosis	I:C0026769
activity	O
;	O
TGF	O
-	I:C1704256
β	I:C1704256
1	I:C1704256
activity	O
is	O
titer	O
-	O
dependent	O
,	O
increased	O
levels	O
were	O
associated	O
with	O
IL	B:C0384648
-	I:C0384648
17	I:C0384648
inhibition	O
;	O
nonresponders	O
patients	O
to	O
IFN	O
-	I:C0254119
β	I:C0254119
1a	I:C0254119
will	O
have	O
initial	O
high	O
IL	O
-	I:C0384648
17	I:C0384648
and	O
low	O
IL	O
-	I:C0085295
10	I:C0085295
and	O
TGF	O
-β	I:C0040690
seric	O
levels	O
.	O

Patients	O
with	O
a	O
Rio	O
score	O
of	O
3	O
had	O
higher	O
initial	O
levels	O
of	O
IL	O
-	I:C0384648
17	I:C0384648
and	O
those	O
with	O
a	O
Rio	O
score	O
of	O
0	O
had	O
higher	O
initial	O
levels	O
of	O
IL	O
-	I:C0085295
10	I:C0085295
and	O
TGF	O
-	I:C1704256
β	I:C1704256
1	I:C1704256
.	O
IFN	O
-	I:C0254119
β	I:C0254119
1a	I:C0254119
decreased	O
IL	O
-	I:C0384648
17	I:C0384648
and	O
increased	O
IL	O
-	I:C0085295
10	I:C0085295
seric	O
levels	O
;	O
IL	O
-	I:C0384648
17	I:C0384648
significantly	O
correlated	O
with	O
multiple	O
sclerosis	I:C0026769
activity	O
;	O
TGF	O
-	I:C1704256
β	I:C1704256
1	I:C1704256
activity	O
is	O
titer	O
-	O
dependent	O
,	O
increased	O
levels	O
were	O
associated	O
with	O
IL	O
-	I:C0384648
17	I:C0384648
inhibition	O
;	O
nonresponders	B:C0243095
patients	O
to	O
IFN	O
-	I:C0254119
β	I:C0254119
1a	I:C0254119
will	O
have	O
initial	O
high	O
IL	O
-	I:C0384648
17	I:C0384648
and	O
low	O
IL	O
-	I:C0085295
10	I:C0085295
and	O
TGF	O
-β	I:C0040690
seric	O
levels	O
.	O

Patients	O
with	O
a	O
Rio	O
score	O
of	O
3	O
had	O
higher	O
initial	O
levels	O
of	O
IL	O
-	I:C0384648
17	I:C0384648
and	O
those	O
with	O
a	O
Rio	O
score	O
of	O
0	O
had	O
higher	O
initial	O
levels	O
of	O
IL	O
-	I:C0085295
10	I:C0085295
and	O
TGF	O
-	I:C1704256
β	I:C1704256
1	I:C1704256
.	O
IFN	O
-	I:C0254119
β	I:C0254119
1a	I:C0254119
decreased	O
IL	O
-	I:C0384648
17	I:C0384648
and	O
increased	O
IL	O
-	I:C0085295
10	I:C0085295
seric	O
levels	O
;	O
IL	O
-	I:C0384648
17	I:C0384648
significantly	O
correlated	O
with	O
multiple	O
sclerosis	I:C0026769
activity	O
;	O
TGF	O
-	I:C1704256
β	I:C1704256
1	I:C1704256
activity	O
is	O
titer	O
-	O
dependent	O
,	O
increased	O
levels	O
were	O
associated	O
with	O
IL	O
-	I:C0384648
17	I:C0384648
inhibition	O
;	O
nonresponders	O
patients	O
to	O
IFN	B:C0254119
-	I:C0254119
β	I:C0254119
1a	I:C0254119
will	O
have	O
initial	O
high	O
IL	O
-	I:C0384648
17	I:C0384648
and	O
low	O
IL	O
-	I:C0085295
10	I:C0085295
and	O
TGF	O
-β	I:C0040690
seric	O
levels	O
.	O

Patients	O
with	O
a	O
Rio	O
score	O
of	O
3	O
had	O
higher	O
initial	O
levels	O
of	O
IL	O
-	I:C0384648
17	I:C0384648
and	O
those	O
with	O
a	O
Rio	O
score	O
of	O
0	O
had	O
higher	O
initial	O
levels	O
of	O
IL	O
-	I:C0085295
10	I:C0085295
and	O
TGF	O
-	I:C1704256
β	I:C1704256
1	I:C1704256
.	O
IFN	O
-	I:C0254119
β	I:C0254119
1a	I:C0254119
decreased	O
IL	O
-	I:C0384648
17	I:C0384648
and	O
increased	O
IL	O
-	I:C0085295
10	I:C0085295
seric	O
levels	O
;	O
IL	O
-	I:C0384648
17	I:C0384648
significantly	O
correlated	O
with	O
multiple	O
sclerosis	I:C0026769
activity	O
;	O
TGF	O
-	I:C1704256
β	I:C1704256
1	I:C1704256
activity	O
is	O
titer	O
-	O
dependent	O
,	O
increased	O
levels	O
were	O
associated	O
with	O
IL	O
-	I:C0384648
17	I:C0384648
inhibition	O
;	O
nonresponders	O
patients	O
to	O
IFN	O
-	I:C0254119
β	I:C0254119
1a	I:C0254119
will	O
have	O
initial	O
high	O
IL	B:C0384648
-	I:C0384648
17	I:C0384648
and	O
low	O
IL	O
-	I:C0085295
10	I:C0085295
and	O
TGF	O
-β	I:C0040690
seric	O
levels	O
.	O

Patients	O
with	O
a	O
Rio	O
score	O
of	O
3	O
had	O
higher	O
initial	O
levels	O
of	O
IL	O
-	I:C0384648
17	I:C0384648
and	O
those	O
with	O
a	O
Rio	O
score	O
of	O
0	O
had	O
higher	O
initial	O
levels	O
of	O
IL	O
-	I:C0085295
10	I:C0085295
and	O
TGF	O
-	I:C1704256
β	I:C1704256
1	I:C1704256
.	O
IFN	O
-	I:C0254119
β	I:C0254119
1a	I:C0254119
decreased	O
IL	O
-	I:C0384648
17	I:C0384648
and	O
increased	O
IL	O
-	I:C0085295
10	I:C0085295
seric	O
levels	O
;	O
IL	O
-	I:C0384648
17	I:C0384648
significantly	O
correlated	O
with	O
multiple	O
sclerosis	I:C0026769
activity	O
;	O
TGF	O
-	I:C1704256
β	I:C1704256
1	I:C1704256
activity	O
is	O
titer	O
-	O
dependent	O
,	O
increased	O
levels	O
were	O
associated	O
with	O
IL	O
-	I:C0384648
17	I:C0384648
inhibition	O
;	O
nonresponders	O
patients	O
to	O
IFN	O
-	I:C0254119
β	I:C0254119
1a	I:C0254119
will	O
have	O
initial	O
high	O
IL	O
-	I:C0384648
17	I:C0384648
and	O
low	O
IL	B:C0085295
-	I:C0085295
10	I:C0085295
and	O
TGF	O
-β	I:C0040690
seric	O
levels	O
.	O

Patients	O
with	O
a	O
Rio	O
score	O
of	O
3	O
had	O
higher	O
initial	O
levels	O
of	O
IL	O
-	I:C0384648
17	I:C0384648
and	O
those	O
with	O
a	O
Rio	O
score	O
of	O
0	O
had	O
higher	O
initial	O
levels	O
of	O
IL	O
-	I:C0085295
10	I:C0085295
and	O
TGF	O
-	I:C1704256
β	I:C1704256
1	I:C1704256
.	O
IFN	O
-	I:C0254119
β	I:C0254119
1a	I:C0254119
decreased	O
IL	O
-	I:C0384648
17	I:C0384648
and	O
increased	O
IL	O
-	I:C0085295
10	I:C0085295
seric	O
levels	O
;	O
IL	O
-	I:C0384648
17	I:C0384648
significantly	O
correlated	O
with	O
multiple	O
sclerosis	I:C0026769
activity	O
;	O
TGF	O
-	I:C1704256
β	I:C1704256
1	I:C1704256
activity	O
is	O
titer	O
-	O
dependent	O
,	O
increased	O
levels	O
were	O
associated	O
with	O
IL	O
-	I:C0384648
17	I:C0384648
inhibition	O
;	O
nonresponders	O
patients	O
to	O
IFN	O
-	I:C0254119
β	I:C0254119
1a	I:C0254119
will	O
have	O
initial	O
high	O
IL	O
-	I:C0384648
17	I:C0384648
and	O
low	O
IL	O
-	I:C0085295
10	I:C0085295
and	O
TGF	B:C0040690
-β	I:C0040690
seric	O
levels	O
.	O

Patients	O
with	O
a	O
Rio	O
score	O
of	O
3	O
had	O
higher	O
initial	O
levels	O
of	O
IL	O
-	I:C0384648
17	I:C0384648
and	O
those	O
with	O
a	O
Rio	O
score	O
of	O
0	O
had	O
higher	O
initial	O
levels	O
of	O
IL	O
-	I:C0085295
10	I:C0085295
and	O
TGF	O
-	I:C1704256
β	I:C1704256
1	I:C1704256
.	O
IFN	O
-	I:C0254119
β	I:C0254119
1a	I:C0254119
decreased	O
IL	O
-	I:C0384648
17	I:C0384648
and	O
increased	O
IL	O
-	I:C0085295
10	I:C0085295
seric	O
levels	O
;	O
IL	O
-	I:C0384648
17	I:C0384648
significantly	O
correlated	O
with	O
multiple	O
sclerosis	I:C0026769
activity	O
;	O
TGF	O
-	I:C1704256
β	I:C1704256
1	I:C1704256
activity	O
is	O
titer	O
-	O
dependent	O
,	O
increased	O
levels	O
were	O
associated	O
with	O
IL	O
-	I:C0384648
17	I:C0384648
inhibition	O
;	O
nonresponders	O
patients	O
to	O
IFN	O
-	I:C0254119
β	I:C0254119
1a	I:C0254119
will	O
have	O
initial	O
high	O
IL	O
-	I:C0384648
17	I:C0384648
and	O
low	O
IL	O
-	I:C0085295
10	I:C0085295
and	O
TGF	O
-β	I:C0040690
seric	B:C0229671
levels	O
.	O

